RxDoctor Payments Data

Ann Bartee, NP

Family · Duncan, SCNPI 1730569328

Payments from drug & device makers

$1,671in general payments, 2019–2025

Across 92 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$335
  • Exact Sciences$236
  • GSK$169
  • Novo Nordisk$145
  • Abbott$143
  • Bayer$119
  • plus $524 from 11 others

What the payments were for

  • Food & beverage$1,671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,671 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$29,062
Medicare patients
94
Services billed
544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$63,964
OzempicSemaglutide31$51,228
FarxigaDapagliflozin Propanediol19$24,345
JanuviaSitagliptin Phosphate12$18,784
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,904
Atorvastatin Calcium257$2,077
Albuterol Sulfate HfaAlbuterol Sulfate58$1,436
Losartan Potassium133$990
Rosuvastatin Calcium61$871
Omeprazole68$804
Lisinopril130$781
Metformin Hcl ErMetformin Hcl93$732
SynthroidLevothyroxine Sodium15$701
Venlafaxine Hcl12$701
Gabapentin44$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$145$51,22831 claims
AstraZenecaFarxiga$114$24,34519 claims
GSKTrelegy Ellipta$169$7,90411 claims
AbbVieSynthroid$335$70115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Duncan

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →